In multiple myeloma, autologous stem cell transplants are seldom curative. Novel strategies are thus needed. Recently clinical studies using myeloma vaccines and activated immune cells provided significant insight into their efficacy when given alone and suggests that combining therapies could significantly augment anti-tumor immunity. A recent study combining the activated T cells with a pneumonia vaccine significantly augmented vaccine responses. With experience from these prior studies, we thus propose to combine the use of myeloma vaccines with activated T cells in autologous transplants as a strategy to improve myeloma-specific immune responses.